Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Gross Profit (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Gross Profit for 4 consecutive years, with $90.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit changed N/A to $90.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $155.8 million, a N/A change, with the full-year FY2025 number at $187.7 million, changed N/A from a year prior.
  • Gross Profit was $90.9 million for Q4 2025 at Soleno Therapeutics, up from $64.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $90.9 million in Q4 2025 to a low of $64.9 million in Q3 2025.